NuGilead You seem to imply CytoDyn is wasting its
Post# of 148282
(Total Views: 604)
Posted On: 08/18/2019 10:26:20 AM
NuGilead
You seem to imply CytoDyn is wasting its time and valuable cash pursuing the cancer indication. Do you understand that the cancer reduction in the preclinical trials have been overwhelming successful in reducing not only tumor size but also tumor metastatic burden. The animal model of mTNBC showed a 98% reduction in metastasis! If results are even half this good in humans, our fundraising problems are over.
Image-1.jpg
https://www.cytodyn.com/newsroom/press-releas...ta-showing
Also, if you listen to the last investor conference call Dr. Bruce Patterson states he has discovered a MOA (mechanism of action) involving CCR5 on T regulatory cells, which protect the cancer from the bodies immune system. He states Leronlimab can inhibit CCR5 on the T Reg cells to allow the bodies immune system to fight the tumor without being blocked by the T Reg cells. This is HUGE!
Even more amazing Dr. Nader quotes Dr. Linder in a Proactive Investor interview stating He has discovered yet another MOA with cancer. Dr.Linder has discovered in his colon cancer research that Leronlimab stops angiogenesis! This is even MORE HUGER!
So, when you state that BP doesn’t think Leronlimab has a good chance in cancer, I think I will trust the opinion of the many leading oncology doctors working with Leronlimab!
You seem to imply CytoDyn is wasting its time and valuable cash pursuing the cancer indication. Do you understand that the cancer reduction in the preclinical trials have been overwhelming successful in reducing not only tumor size but also tumor metastatic burden. The animal model of mTNBC showed a 98% reduction in metastasis! If results are even half this good in humans, our fundraising problems are over.
Image-1.jpg
https://www.cytodyn.com/newsroom/press-releas...ta-showing
Also, if you listen to the last investor conference call Dr. Bruce Patterson states he has discovered a MOA (mechanism of action) involving CCR5 on T regulatory cells, which protect the cancer from the bodies immune system. He states Leronlimab can inhibit CCR5 on the T Reg cells to allow the bodies immune system to fight the tumor without being blocked by the T Reg cells. This is HUGE!
Even more amazing Dr. Nader quotes Dr. Linder in a Proactive Investor interview stating He has discovered yet another MOA with cancer. Dr.Linder has discovered in his colon cancer research that Leronlimab stops angiogenesis! This is even MORE HUGER!
So, when you state that BP doesn’t think Leronlimab has a good chance in cancer, I think I will trust the opinion of the many leading oncology doctors working with Leronlimab!
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼